

Parallel Regulatory-HTA Scientific Advice

Health Technology Assessment Network


Results of Pilot





Making the case for parallel advice

56 products



http://www.efpia.eu/documents/189/61/HTA-Accelerator-In-Depth-Analysis-Final-report



Why needed?

Exclusion of appropriate comparator

Absence of data in a relevant subgroup

Cancer review* - gaps, delays

The Problem

Valid reasons for divergences possible but leads to pressure

Should be no avoidable reasons based on nature/scope evidence


*Ann <u>Oncol.</u> 2016 Jan; 27(1): 96-105






Can Parallel Advice Help?

Reconciled within 1 plan/trial?





What have we learned?



Completed parallel advice procedures / year



What have we learned?

- Public consultation
- Comments and outcomes published
- High level of support
- Constructive changes
- Worked with EUnetHTA/HTAs
- Refined Guidance

- HTAs
 - o Lists of issues
 - o Written answers
 - o Coordinator
 - o Closed sessions
- Multi-stakeholder procedure
- One of EUnetHTA collaborative
- Incorporated SEED learnings



Some issues

- "Industry applicants select agencies from big markets, ..."
- "Simplification of agreements and fees" resourcing?
- "A central administrative infrastructure"

- Roles and remits = respected
- Relationship advice and regulatory opinion maker = vital
- Data confidentiality = protected
- 6 Parallel advice regulatory- HTA HTAN



What have we learned?



Small Medium Enterprises

Support and guidance needed

Observations for final model

- •Principles
- Processes





Parallel Advice – Regulators and Health Technology Assessment Bodies (HTAs)

- Pilot concluded

 learnings strengths and weaknesses
- Risk benefit+, now interim phase, future development necessary
- Collaborative stakeholder interactions on patients' access to new and important medicines
- ✓ Will continue on operational basis
- EMA willing to work with EUnetHTA & all stakeholders to move



Acknowledgements Steve Cordeiro, Lisbeth Barkholt, Giovanni Tafuri

Thank you for your attention

Further information

Contact me at Jane.moseley@ema.europa.eu

European Medicines Agency

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 7149 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

